March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Prognostic Indicators And Outcome Measures For Patients With Neovascular Age-related Macular Degeneration Undergoing Treatment With Intravitreal Ranibizumab
Author Affiliations & Notes
  • Sarah Sabour-Pickett
    Institute of Vision Research, Waterford, Ireland
    Dublin Institute of Technology, Dublin, Ireland
  • James Loughman
    Optometry,
    Dublin Institute of Technology, Dublin, Ireland
  • John M. Nolan
    Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
  • Konrad Pesudovs
    NHMRC Ctr Clin Eye Res/Optometry, Flinders University SA, Bedford Park, Australia
  • Stephen Beatty
    Institute of Vision Research, Waterford, Ireland
  • Footnotes
    Commercial Relationships  Sarah Sabour-Pickett, This study was funded by Novartis Pharma AG (F); James Loughman, None; John M. Nolan, None; Konrad Pesudovs, None; Stephen Beatty, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4397. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Sabour-Pickett, James Loughman, John M. Nolan, Konrad Pesudovs, Stephen Beatty; Prognostic Indicators And Outcome Measures For Patients With Neovascular Age-related Macular Degeneration Undergoing Treatment With Intravitreal Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4397.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess visual function, and its response to serial intravitreal ranibizumab (Lucentis, Genentech), in patients with neovascular age-related macular degeneration (nv-AMD).

Methods: : Forty seven eyes of 47 patients with nv-AMD (with CDVA LogMAR 0.7 or better) undergoing monthly intravitreal injections of ranibizumab were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests and by questionnaire, while mean foveal thickness (MFT) and mean foveal volume (MFV) were determined by optical coherence tomography (OCT), all at monthly intervals.

Results: : Group mean (±sd) MFT reduced significantly from baseline (233 [±59]) to exit (205 [±40]) (p=0.001). Visual acuity and questionnaire scores exhibited no change between baseline and exit visits (p=0.48 and p=0.31 respectively). Measures of visual function that did exhibit statistically significant improvements (p<0.05 for all) included: mean reading speed, mesopic contrast sensitivity (CS) at low and high spatial frequencies, mesopic glare disability (GD) at low and medium spatial frequencies, and retinotopic ocular sensitivity (ROS) at all eccentricities.

Conclusions: : Eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. It appears that CS under mesopic conditions at low and high spatial frequencies, mean reading speed, GD at low spatial frequencies and ROS would be more sensitive outcome measures than CDVA for patients undergoing this treatment, at least in eyes where baseline CDVA is logMAR 0.7 or better. Such outcome measures should be considered in the design of studies investigating nv-AMD.

Keywords: age-related macular degeneration • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×